Why is Dianthus Therapeutics stock gaining today?

Dianthus Therapeutics stock edged up 0.8% in after-hours trading to reach $80, lifted by Roth/MKM’s initiation of coverage with a Buy rating and a $113 price target — the latest in a string of bullish analyst actions that have kept the clinical-stage biotech firmly in institutional focus. The initiation brings the total analyst buy count to 18, with no Hold or Sell ratings on record, underscoring the degree of conviction Wall Street has built around the company’s complement therapeutics pipeline.

The Roth/MKM call adds to a well-populated bull camp that includes price targets stretching as high as $158 from H.C. Wainwright and $156 from Citi, with JPMorgan’s Overweight initiation from September carrying a $135 target. Wells Fargo’s reiterated Buy from October 18 also kept sentiment constructive heading into today’s session, and with next earnings scheduled for November 5, investor attention on the name remains elevated.

The broader market provided a modestly supportive backdrop, with the S&P 500 up 0.07% and the Nasdaq edging fractionally higher, as investors navigated a week packed with central bank meetings — including the FOMC — and digested the prior session’s AI-driven rally. The macro environment was neither a headwind nor a meaningful tailwind for biotech specifically, leaving company-specific catalysts as the dominant driver for DNTH.

Taken together, the Roth/MKM initiation served as the immediate spark for today’s after-hours move, reinforcing a narrative of broad institutional conviction around Dianthus’s claseprubart program and its multiple late-stage trial readouts on the horizon, even as the stock continues to trade at a meaningful discount to the consensus analyst price target.